Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 43% ± 15% | |
peripheral blood | 20 studies | 43% ± 16% | |
brain | 14 studies | 34% ± 17% | |
intestine | 12 studies | 35% ± 14% | |
eye | 11 studies | 34% ± 16% | |
kidney | 9 studies | 43% ± 6% | |
liver | 7 studies | 39% ± 13% | |
bone marrow | 6 studies | 28% ± 9% | |
lymph node | 6 studies | 46% ± 15% | |
heart | 6 studies | 27% ± 3% | |
pancreas | 5 studies | 50% ± 16% | |
placenta | 5 studies | 25% ± 9% | |
adipose | 5 studies | 28% ± 13% | |
prostate | 5 studies | 27% ± 7% | |
uterus | 4 studies | 49% ± 12% | |
esophagus | 4 studies | 37% ± 25% | |
breast | 4 studies | 38% ± 10% | |
adrenal gland | 3 studies | 41% ± 6% | |
stomach | 3 studies | 35% ± 19% | |
thymus | 3 studies | 55% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 7466.43 | 21 / 21 | 100% | 66.11 | 504 / 504 |
esophagus | 100% | 7248.00 | 1445 / 1445 | 100% | 52.70 | 183 / 183 |
liver | 100% | 4278.59 | 226 / 226 | 100% | 51.97 | 406 / 406 |
ovary | 100% | 7918.17 | 180 / 180 | 100% | 68.19 | 430 / 430 |
pancreas | 100% | 6046.79 | 328 / 328 | 100% | 72.08 | 178 / 178 |
prostate | 100% | 8087.16 | 245 / 245 | 100% | 106.91 | 502 / 502 |
stomach | 100% | 6601.07 | 359 / 359 | 100% | 55.04 | 286 / 286 |
thymus | 100% | 7059.22 | 653 / 653 | 100% | 105.30 | 605 / 605 |
uterus | 100% | 7507.48 | 170 / 170 | 100% | 74.03 | 459 / 459 |
breast | 100% | 6632.74 | 459 / 459 | 100% | 84.20 | 1117 / 1118 |
kidney | 100% | 7269.21 | 89 / 89 | 100% | 81.06 | 900 / 901 |
lung | 100% | 5759.08 | 577 / 578 | 100% | 71.68 | 1155 / 1155 |
intestine | 100% | 7473.38 | 966 / 966 | 100% | 61.83 | 526 / 527 |
adrenal gland | 100% | 8083.51 | 258 / 258 | 100% | 84.23 | 229 / 230 |
brain | 99% | 3293.76 | 2615 / 2642 | 100% | 48.47 | 705 / 705 |
skin | 100% | 4680.65 | 1807 / 1809 | 98% | 44.79 | 464 / 472 |
adipose | 100% | 6381.79 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8686.19 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 91.78 | 29 / 29 |
muscle | 100% | 9576.36 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7320.98 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 64.23 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.72 | 1 / 1 |
heart | 99% | 8705.54 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 4309.40 | 907 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 42.72 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031145 | Biological process | anaphase-promoting complex-dependent catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0051301 | Biological process | cell division |
GO_0051445 | Biological process | regulation of meiotic cell cycle |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0000776 | Cellular component | kinetochore |
GO_0005680 | Cellular component | anaphase-promoting complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005515 | Molecular function | protein binding |
Gene name | ANAPC16 |
Protein name | Anaphase-promoting complex subunit 16 (Cyclosome subunit 16) Anaphase-promoting complex subunit 16 (APC16) (Cyclosome subunit 16) |
Synonyms | C10orf104 CENP-27 |
Description | FUNCTION: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. . FUNCTION: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. . |
Accessions | ENST00000299381.5 Q96DE5 ENST00000615507.4 ENST00000621663.4 A0A087WUN5 |